Evidence map›Paper›PMID 30121200›Full record

ArticleNeuropharmacology2018

Revisiting cannabinoid receptor 2 expression and function in murine retina.

Joanna Borowska-Fielding, Natalia Murataeva, Ben Smith, Anna-Maria Szczesniak, Emma Leishman, Laura Daily, J Thomas Toguri, Cecelia J Hillard, Julian Romero, Heather Bradshaw and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Joanna Borowska-FieldingDepartment of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Natalia MurataevaDepartment of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.
Ben SmithPhysiology and Biophysics, Dalhousie University, Halifax, NS, Canada.
Anna-Maria SzczesniakDepartment of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Emma LeishmanDepartment of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.
Laura DailyDepartment of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.
J Thomas ToguriDepartment of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Cecelia J HillardDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
Julian RomeroFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223, Madrid, Spain.
Heather BradshawDepartment of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.
Melanie E M KellyDepartment of Pharmacology, Dalhousie University, Halifax, NS, Canada; Physiology and Biophysics, Dalhousie University, Halifax, NS, Canada; Anesthesia, Dalhousie University, Halifax, NS, Canada.
Alex StraikerDepartment of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA. Electronic address: straiker@indiana.edu.
Dalhousie University · CAIndiana University Bloomington · USMedical College of Wisconsin · USUniversidad Francisco de Vitoria · ES

Funding

Harnessing endogenous cannabinoids for ocular healthR01EY024625 · NEI · TRUSTEES OF INDIANA UNIVERSITY · PI STRAIKER, ALEXANDER J · 2014 to 2017
$1.3M
NEI NIH HHS R01 EY024625NIH HHS EY024625
6 · The paper itself

Abstract

The cannabinoid receptor CB2 plays a significant role in the regulation of immune function whereas neuronal expression remains a subject of contention. Multiple studies have described CB2 in retina and a recent study showed that CB2 deletion altered retinal visual processing. We revisited CB2 expression using immunohistochemistry and a recently developed CB2-eGFP reporter mouse. We examined the consequence of acute vs. prolonged CB2 deactivation on the electroretinogram (ERG) responses. We also examined lipidomics in CB2 knockout mice and potential changes in microglia using Scholl analysis. Consistent with a published report, in CB2 receptor knockout mice see an increased ERG scotopic a-wave, as well as stronger responses in dark adapted cone-driven ON bipolar cells and, to a lesser extent cone-driven ON bipolar cells early in light adaptation. Significantly, however, acute block with CB2 antagonist, AM630, did not mimic the results observed in the CB2 knockout mice whereas chronic (7 days) block did. Immunohistochemical studies show no CB2 in retina under non-pathological conditions, even with published antibodies. Retinal CB2-eGFP reporter signal is minimal under baseline conditions but upregulated by intraocular injection of either LPS or carrageenan. CB2 knockout mice see modest declines in a broad spectrum of cannabinoid-related lipids. The numbers and morphology of microglia were unaltered. In summary minimal CB2 expression is seen in healthy retina. CB2 appears to be upregulated under pathological conditions. Previously reported functional consequences of CB2 deletion are an adaptive response to prolonged blockade of these receptors. CB2 therefore impacts retinal signaling but perhaps in an indirect, potentially extra-ocular fashion.

Indexed as

Adaptation, OcularAnimalsCannabinoid Receptor AntagonistsCarrageenanElectroretinographyFemaleImmunohistochemistryIndolesInflammationLipid MetabolismLipopolysaccharidesMaleMiceMice, KnockoutReceptor, Cannabinoid, CB2RetinaCannabinoid Receptor AntagonistsCarrageenanIndolesiodopravadolineLipopolysaccharidesReceptor, Cannabinoid, CB2CannabinoidCB2ElectroretinogramERGRetina

Identifiers

PMID30121200
PMCPMC6314309
OpenAlexW2885238676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.